Skip to main content
. 2019 Apr 21;35(9):1570–1576. doi: 10.1093/ndt/gfz064

FIGURE 2.

FIGURE 2

Predicted risk change for (A) kidney and (B) HF outcomes for patients with UACR >200 mg/g, based on changes in single risk markers and the integrated effects of all risk markers. Circles indicate the point estimates of the percentage mean change in relative risk induced by dapagliflozin compared with placebo and is given with its 95% CI.